Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H22Cl2N2O6 |
Molecular Weight | 457.304 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(COC(N)=O)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC(C)C
InChI
InChIKey=WTOVRSWDBLIFHU-UHFFFAOYSA-N
InChI=1S/C20H22Cl2N2O6/c1-9(2)30-19(26)16-13(8-29-20(23)27)24-10(3)14(18(25)28-4)15(16)11-6-5-7-12(21)17(11)22/h5-7,9,15,24H,8H2,1-4H3,(H2,23,27)
Molecular Formula | C20H22Cl2N2O6 |
Molecular Weight | 457.304 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/18465561Curator's Comment: description was created based on several sources, including
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18465561
Curator's Comment: description was created based on several sources, including
Lemildipine is a 1,4-dihydropyridine calcium channel blocker which is under phase III development by Banyu (Merck and Co), in Japan, for its potential to treat hypertension and cerebrovascular ischemia. In one study, involving five patients with essential hypertension accompanied by cerebrovascular disorder, lemildipine, administered orally at doses of 5 to 20 mg/day, significantly lowered blood pressure and increased cerebral blood flow. Another study in 31 patients with essential hypertension demonstrated that lemildipine has significant pressure lowering effects without affecting serum lipids. Worldwide rights to market the drug have been assigned to Kowa in Japan.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363032 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3712868 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18465561
5 to 20 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8773452
In a whole-cell configuration with voltage clamp, the blocking effect of NB-818 (LEMILDIPINE) on L-type Ca2+ current (ICa) in guinea-pig ventricular cells appeared much more slowly than that of nifedipine and was hardly washed out. The potency of NB-818 to block ICa was markedly enhanced under depolarized conditions compared to that under polarized conditions. Such a voltage-dependent blocking action on ICa was less pronounced for nifedipine. These results indicate that NB-818 is a slow-acting Ca2+ channel antagonist with much high vascular selectivity. Its vascular selectivity may be at least in part related to the marked voltage-dependent inhibition of ICa.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:02 GMT 2023
by
admin
on
Fri Dec 15 16:02:02 GMT 2023
|
Record UNII |
R3BD0YW4ZF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2104876
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
DTXSID8048812
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
125729-29-5
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
SUPERSEDED | |||
|
R3BD0YW4ZF
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
65953
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
94739-29-4
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
7108
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
100000082587
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
SUB08428MIG
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY | |||
|
C170102
Created by
admin on Fri Dec 15 16:02:02 GMT 2023 , Edited by admin on Fri Dec 15 16:02:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |